Autologous Adult Live Cultured Chondrocytes Implantation Show Good Mid-Term Efficacy In Cartilage Defects Of The Knee Joint
- byDoctor News Daily Team
- 16 July, 2025
- 0 Comments
- 0 Mins

Research shows autologous chondrocyte implantation (ACI) is a promising treatment for articular cartilage lesions. In this study, Shirish Pathak et al assessed mid-term efficacy and safety of gel-based ACI or autologous adult live cultured chondrocytes implantation in patients with cartilage defects of the knee joint. The study was published in "International Orthopaedics" journal.
In this prospective, open-label study, patients (19–38 years) with focal, international cartilage repair society grade III or IV articular cartilage defects of the knee joint were enrolled at four centres across India.
Punch biopsy was conducted to harvest cartilage, from which chondrocytes were isolated and cultured, and the characterised chondrocytes were implanted into the cartilage defect. Key efficacy outcomes were assessed by quantitative changes in international knee documentation committee (IKDC), visual analogue scale (VAS) scores, and qualitative changes in magnetic resonance imaging at six months and four years from baseline.
• Of the14 patients enrolled in the study, all patients completed the six month follow-up and 11 completed the four year follow-up.
• The IKDC score improved significantly from 32.84±9.25 at baseline to 67.49±13.03 at six months (mean difference [MD] 34.66±13.00, p < 0.0001) and to 60.18±10.33 at four years (MD 28.21±15.14, p=0.0001).
• The VAS score reduced from 72.00±14.40 at baseline to 16.64±17.03 at six months (MD 55.36±24.50, p< 0.0001) and further to 12.72±9.05 at four years (MD 62.09±10.66, p< 0.0001).
• All patients showed improvement on MRI of the knee joint.
• No adverse events were reported.
The authors concluded that - this study shows that gel-based ACI alleviates pain and improves functional activity with no side-effects in patients with articular cartilage defects of the knee. Overall, CARTIGROW® showed good mid-term efficacy; however, substantiating these results in real clinical setting would be of future interest.
Further reading:
Efficacy and safety of CARTIGROW® in patients with articular cartilage defects of the knee joint: a four year prospective studys
Shirish Pathak, Deepak Chaudhary, K. Raghuveer Reddy et al
International Orthopaedics (2022) 46:1313–1321
https://doi.org/10.1007/s00264-022-05369-2
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
Recent News
Cycling Associated With Frequent Traumatic Spine I...
- 31 August, 2021
Cannabis Use During Pregnancy Impacts Placenta And...
- 06 July, 2025
HIV Screening Should Be Initiated At Age 15 In Ado...
- 03 January, 2022
Daily Newsletter
Get all the top stories from Blogs to keep track.
0 Comments
Post a comment
No comments yet. Be the first to comment!